Nevertheless, although phosphorus-based PSMA inhibitors play a subordinate role in today’s PSMA-targeted diagnostics and treatment of prostate cancer, ground-breaking work with phosphorus-containing inhibitors served as the starting point for the development of current state-of-the-art molecules. Here, FOLH1 is linked to prostate cancer.